PMID- 32621841
OWN - NLM
STAT- MEDLINE
DCOM- 20201007
LR  - 20210110
IS  - 1872-7492 (Electronic)
IS  - 0168-1702 (Print)
IS  - 0168-1702 (Linking)
VI  - 288
DP  - 2020 Oct 15
TI  - Epitope-based peptide vaccines predicted against novel coronavirus disease caused 
      by SARS-CoV-2.
PG  - 198082
LID - S0168-1702(20)30388-9 [pii]
LID - 10.1016/j.virusres.2020.198082 [doi]
AB  - The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected millions of 
      people with a large number of deaths across the globe. The existing therapies are 
      limited in dealing with SARS-CoV-2 due to the sudden appearance of the virus. 
      Therefore, vaccines and antiviral medicines are in desperate need. We took 
      immune-informatics approaches to identify B- and T-cell epitopes for surface 
      glycoprotein (S), membrane glycoprotein (M) and nucleocapsid protein (N) of 
      SARS-CoV-2, followed by estimating their antigenicity and interactions with the 
      human leukocyte antigen (HLA) alleles. Allergenicity, toxicity, physiochemical 
      properties analysis and stability were examined to confirm the specificity and 
      selectivity of the epitope candidates. We identified a total of five B cell 
      epitopes in RBD of S protein, seven MHC class-I, and 18 MHC class-II binding 
      T-cell epitopes from S, M and N protein which showed non-allergenic, non-toxic 
      and highly antigenic features and non-mutated in 55,179 SARS-CoV-2 virus strains 
      until June 25, 2020. The epitopes identified here can be a potentially good 
      candidate repertoire for vaccine development.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Lin, Li
AU  - Lin L
AD  - Beijing Advanced Innovation Center for Biomedical Engineering, Beihang 
      University, Beijing, China; School of Biological Science and Medical Engineering, 
      Beihang University, Beijing China.
FAU - Ting, Sun
AU  - Ting S
AD  - Beijing Advanced Innovation Center for Biomedical Engineering, Beihang 
      University, Beijing, China; School of Biological Science and Medical Engineering, 
      Beihang University, Beijing China.
FAU - Yufei, He
AU  - Yufei H
AD  - School of Biological Science and Medical Engineering, Beihang University, Beijing 
      China.
FAU - Wendong, Li
AU  - Wendong L
AD  - Beijing Advanced Innovation Center for Biomedical Engineering, Beihang 
      University, Beijing, China; School of Biological Science and Medical Engineering, 
      Beihang University, Beijing China.
FAU - Yubo, Fan
AU  - Yubo F
AD  - Beijing Advanced Innovation Center for Biomedical Engineering, Beihang 
      University, Beijing, China; School of Biological Science and Medical Engineering, 
      Beihang University, Beijing China. Electronic address: yubofan@buaa.edu.cn.
FAU - Jing, Zhang
AU  - Jing Z
AD  - Beijing Advanced Innovation Center for Biomedical Engineering, Beihang 
      University, Beijing, China. Electronic address: jz2716@buaa.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200701
PL  - Netherlands
TA  - Virus Res
JT  - Virus research
JID - 8410979
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Coronavirus M Proteins)
RN  - 0 (Coronavirus Nucleocapsid Proteins)
RN  - 0 (Epitopes, B-Lymphocyte)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Nucleocapsid Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (Viral Vaccines)
RN  - 0 (membrane protein, SARS-CoV-2)
RN  - 0 (nucleocapsid phosphoprotein, SARS-CoV-2)
SB  - IM
MH  - Amino Acid Sequence
MH  - Betacoronavirus/drug effects/*immunology
MH  - Binding Sites
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/immunology/prevention & control/virology
MH  - Coronavirus M Proteins
MH  - Coronavirus Nucleocapsid Proteins
MH  - Epitopes, B-Lymphocyte/*chemistry/immunology/metabolism
MH  - Epitopes, T-Lymphocyte/*chemistry/immunology/metabolism
MH  - Humans
MH  - Immunogenicity, Vaccine
MH  - Models, Molecular
MH  - Nucleocapsid Proteins/*chemistry/immunology/metabolism
MH  - Pandemics/prevention & control
MH  - Phosphoproteins
MH  - Pneumonia, Viral/immunology/prevention & control/virology
MH  - Protein Binding
MH  - Protein Conformation, alpha-Helical
MH  - Protein Conformation, beta-Strand
MH  - Protein Interaction Domains and Motifs
MH  - SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus/*chemistry/immunology/metabolism
MH  - Viral Matrix Proteins/*chemistry/immunology/metabolism
MH  - Viral Vaccines/administration & dosage/biosynthesis/*chemistry
PMC - PMC7328648
OTO - NOTNLM
OT  - B-cell epitope
OT  - Immune-informatics
OT  - SARS-CoV-2
OT  - Spike protein
OT  - T-cell epitope
OT  - Vaccine design
COIS- The authors declare no potential conflicts of interest.
EDAT- 2020/07/06 06:00
MHDA- 2020/10/08 06:00
PMCR- 2020/07/01
CRDT- 2020/07/05 06:00
PHST- 2020/04/12 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/07/06 06:00 [pubmed]
PHST- 2020/10/08 06:00 [medline]
PHST- 2020/07/05 06:00 [entrez]
PHST- 2020/07/01 00:00 [pmc-release]
AID - S0168-1702(20)30388-9 [pii]
AID - 198082 [pii]
AID - 10.1016/j.virusres.2020.198082 [doi]
PST - ppublish
SO  - Virus Res. 2020 Oct 15;288:198082. doi: 10.1016/j.virusres.2020.198082. Epub 2020 
      Jul 1.